![]() ImmusanT ImmusanT is a clinical development-stage biotechnology company focused on an innovative disease-modifying approach to induce immune tolerance in autoimmune diseases. | ![]() Mesoblast Mesoblast specializes in the development of biologic products for the broad field of regenerative medicine. | Harmony Biosciences Harmony Biosciences develops therapies to help patients with unmet medical needs. | Translational Sciences Translational Sciences is a biotechnology company that develops therapeutics for treating acute thrombotic cardiovascular diseases and ischemic stroke. | |
Founding Date | Founding Date 2010 | Founding Date 2004 | Founding Date 2017 | Founding Date 2007 |
Type | Type Private | Type Public | Type Public | Type Private |
Tags | ||||
Locations | Locations Cambridge, US HQ | Locations Melbourne, AU HQ Singapore, SG New York, US | Locations Plymouth Meeting, US HQ | Locations Phoenix, US HQ |
Employees | Employees 2 | Employees 73 | Employees N/A | Employees N/A |
Valuation ($) | Valuation ($) N/A | Valuation ($) 1.2 b | Valuation ($) 2.4 b | Valuation ($) N/A |
Financial | ||||
Revenue (est.) | Revenue (est.) N/A | Revenue (est.) $17.2m (FY, 2025) | Revenue (est.) $868.5m (FY, 2025) | Revenue (est.) N/A |
Cost of goods | Cost of goods N/A | Cost of goods $1.2m (FY, 2025) | Cost of goods $198.3m (FY, 2025) | Cost of goods N/A |
Gross profit | Gross profit N/A | Gross profit $16.1m (FY, 2025) | Gross profit $670.1m (FY, 2025) | Gross profit N/A |
Net income | Net income N/A | Net income ($102.1m) (FY, 2025) | Net income $158.7m (FY, 2025) | Net income N/A |
Funding | ||||
Total funding raised | Total funding raised $ 72.8m | Total funding raised $ 56.2m | Total funding raised $ 270m | Total funding raised N/A |

Mesoblast specializes in the development of biologic products for the broad field of regenerative medicine.
View companyHarmony Biosciences develops therapies to help patients with unmet medical needs.
View companyTranslational Sciences is a biotechnology company that develops therapeutics for treating acute thrombotic cardiovascular diseases and ischemic stroke.
View company